Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Holly Rene Martin"'
Autor:
Molly C. Hardebeck, Holly Rene Martin, Stephen R. D. Johnston, Miguel Martín, Joyce O'Shaughnessy, Masakazu Toi, Jens Huober, Matthew P. Goetz, Valerie Andre, Joohyuk Sohn
Publikováno v:
npj Breast Cancer, Vol 7, Iss 1, Pp 1-5 (2021)
NPJ Breast Cancer
NPJ Breast Cancer
In MONARCH 3, continuous dosing of abemaciclib with an aromatase inhibitor (AI) conferred significant clinical benefit to postmenopausal women with HR+, HER2− advanced breast cancer. We report data for clinically prognostic subgroups: liver metasta
Autor:
Molly C. Hardebeck, Masakazu Toi, Miguel Martin, Matthew P. Goetz, Joyce O'Shaughnessy, V.A. Andre, Angelo Di Leo, Jens Huober, Holly Rene Martin, Stephen R. D. Johnston
Publikováno v:
Cancer Research. 80:P1-19
Background: Abemaciclib plus nonsteroidal aromatase inhibitors (AI) demonstrated efficacy with a tolerable safety profile as initial treatment for postmenopausal women with HR+, HER2− advanced breast cancer in the MONARCH 3 trial. In the intent-to-
Autor:
Matthew P. Goetz, Jens Huober, M. Martin, Molly C. Hardebeck, Holly Rene Martin, Joohyuk Sohn, S.R.D. Johnston, A. Di Leo, V.A. Andre
Publikováno v:
Annals of Oncology. 30:v113-v114
Background In MONARCH 3, a randomized, double-blind, phase 3 trial; continuous dosing of abemaciclib in combination with an AI (anastrozole or letrozole) conferred significant clinical benefit to postmenopausal women with HR+, HER2- ABC. We here repo